The Switzerland-based biotech has raised $22 million from German billionaire Dietmar Hopp and other backers to advance its Alzheimer's vaccine candidate, ACI-35, into clinical trials.
Shares of Intercept Pharmaceuticals went into overdrive this morning, soaring a remarkable 125% on the surprise news that a Phase IIb clinical study for its lead drug funded largely by the NIH ended early after achieving the primary endpoint.
Pharma giant Sanofi is jumping on the clinical trial transparency bandwagon, agreeing to share data with researchers public and private, but the French drugmaker's plan stops short of the sweeping initiatives favored by some of its rivals.
Sanofi is starting the New Year with a resolution to join the open-access movement. But it's keeping the vaults firmly closed on any past data--this is one resolution that applies only to future drug approvals.
Cerenis CEO Jean-Louis Dasseux was so confident he had found the magic HDL bullet that he told reporters and a group of investors that he would hold off on any pharma deal for CER-001 until he could prove that the drug worked in a key trial. But like other high-profile HDL therapies that came before it, CER-001 failed.
If successful the trial--which is due to last two to three years--will culminate in marketing applications to U.S. and European regulators.
Swedish biotech Axelar's lung cancer drug failed to beat out standard docetaxel in a mid-stage trial, but bankroller Karolinska Development isn't giving up, planning to keep studying the drug in hopes of finding a partner.
Tesaro touted positive results for the primary endpoints laid out for the late-stage program it had underway for its top cancer drug prospect rolapitant, but investors soured on the drug after it failed to score secondary goals and drove the biotech's shares down by a hefty 22% this morning.
Vertex Pharmaceuticals' piecemeal approach to the world's cystic fibrosis sufferers took a hit as Kalydeco failed to meet its primary endpoint in a Phase III trial on patients with one form of the disease, sending the company's shares down as much as 6% premarket on Thursday morning before an eventual rebound.
Gilead unveiled a package of stellar late-stage cure rates for its closely-watched hepatitis C combination of the newly approved "nuke" Sovaldi (sofosbuvir) and the NS5A inhibitor ledipasvir, putting it on a short path to the FDA with a new drug application planned for the first quarter of the coming year.